Market Overview

7 U.S. Health Care Penny Stocks With Upside Potential Greater Than 100%

Share:

Want an edge on biotech stocks? Try this.

Learn more about investing in the biotech sector with real-time trading picks from experts like the Biotech Trader.

Today we have shortlisted seven U.S. healthcare penny stocks that have delivered a decent total return (>30.0%) year-to-date. According to the Bloomberg estimated 12-month target price, these stocks are expected to yield strong price returns (>100.0%). During the past one month, all of the stocks have registered price gains with daily average trading volumes in excess of 100,000.


Company Name

Ticker

Exchange

Market Cap
(US$ MN)

Last Price

Average Volume 
(1 Month)

Price Change (1-Month)

Total Return YTD

Target Price*

Upside Potential

Celator Pharmaceuticals Inc

CPXX

NASDAQ

100.7

2.99

472,747

67.0%

52.6%

11.00

267.9%

Anthera Pharmaceuticals Inc

ANTH

NASDAQ

57.3

2.50

613,631

49.7%

58.2%

8.00

220.0%

Alexza Pharmaceuticals Inc

ALXA

NASDAQ

41.5

2.14

190,785

40.8%

43.6%

6.25

192.1%

Athersys Inc

ATHX

NASDAQ

163.6

2.11

793,202

49.6%

33.5%

5.39

155.3%

GenVec Inc

GNVC

NASDAQ

59.2

3.43

112,315

64.1%

64.9%

8.50

147.8%

Apricus Biosciences Inc

APRI

NASDAQ

59.0

1.33

384,091

34.3%

33.0%

2.83

113.0%

Fibrocell Science Inc

FCSC

NASDAQ

156.9

3.84

126,466

61.3%

48.3%

8.13

111.6%

Source: Bloomberg
* 12-month target price

Company Description

Celator Pharmaceuticals Inc (NASDAQ: CPXX) 
Celator Pharmaceuticals, Inc. develops and produces advance biopharmaceutical products. The company researches and distributes therapies to treat cancer, leukemia, and small cell lung cancer through the proper regulation of chemotherapy. Celator Pharmaceuticals serves customers throughout the United States and Canada.

Anthera Pharmaceuticals Inc (NASDAQ: ANTH
Anthera Pharmaceuticals Inc. is a biopharmaceutical company. The company is focused on developing and commercializing anti-inflammatory therapeutics for cardiovascular diseases, lupus and other serious diseases.

Alexza Pharmaceuticals Inc (NASDAQ: ALXA
Alexza Pharmaceuticals, Inc. is a pharmaceutical company focused on the development and commercialization of proprietary products for the treatment of acute and intermittent conditions.

Athersys Inc (NASDAQ: ATHX
Athersys Incorporated is a clinical-stage biotechnology company. The company develops allogeneic stem cell products that focus on treating inflammatory and immune disorders, neurological conditions, cardiovascular disease, and other conditions.

GenVec Inc (NASDAQ: GNVC
GenVec, Inc. is a biopharmaceutical company developing novel therapeutic drugs and vaccines. The company specializes in the treatment of cancers, including pancreatic cancer, esophageal cancer, rectal cancer, and head and neck cancer. The company is also involved in studies involving hearing loss and balance disorders. GenVec also develops vaccines for infectious diseases.

Apricus Biosciences Inc (NASDAQ: APRI
Apricus Biosciences Inc. is a bio-technology company. The company is seeking to monetize its existing product pipeline, including compounds from pre-clinical through Phase 3, currently focused on dermatology, sexual dysfunction and cancer.

 

Fibrocell Science Inc (NASDAQ: FCSC) 
Fibrocell Science, Inc. is a biotechnology company that develops skin and tissue rejuvenation technologies. The company's process multiplies the patient's collagen producing cells and returns them to the patient's skin to treat damage caused by aging, the sun, acne, and burns.

The following article is from one of our external contributors. It does not represent the opinion of Benzinga and has not been edited.

Posted-In: Health Care Small Cap Analysis Trading Ideas General

 

Related Articles (ALXA + ANTH)

View Comments and Join the Discussion!
Loading...

Partner Center

Loading...